Iron Wolf Capital leads Self.co’s €1.2M funding round
Self.co, a Vilnius-based digital health company helping users understand and manage allergies and food intolerances, has raised €2.56 million in a combined grant and venture funding round.
The €1.2 million funding round was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and several angel investors. Self.co received the €1.36 million grant from Innovation Agency Lithuania. The funding will support the expansion into new markets and further development of Self.co’s proprietary testing technology and long-term management tools.
Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital, says: “As DeepTech investors, we back technologies with the potential to transform established industries, and that’s exactly what Self.co is doing in allergy diagnostics and care. This is a large, fast-growing market still underserved by current solutions. Tautvydas and the team combine exceptional industry insight with strong execution, giving them a rare founder-market fit. Self.co’s platform addresses long-standing pain points for patients and clinicians, positioning the company to redefine allergy care globally. We’re proud to lead this round and support their mission to deliver meaningful healthcare innovation at scale.”
Founded in 2015 by Gintautas Gylys, Self.co is a digital health and diagnostics company helping people understand allergy-like symptoms through molecular testing and expert guidance.
Tautvydas Gylys, co-founder and CEO of Self.co, said: “Millions of people live with allergy-like symptoms but without a real understanding of what’s causing them or what to do about it. We’ve taken advanced diagnostic technology and built a simple test system that gives anyone clear, medically valid answers without the high cost or long wait.
Self.co will use the new funding to develop a comprehensive digital health platform that serves as an entry point for people experiencing allergy-like symptoms. The platform will include advanced symptom questionnaires to pinpoint conditions, expanded test offerings, and better integration with traditional healthcare systems.
Self.co aims to become the go-to digital health platform for top-to-bottom allergy care in Europe by 2030.
For more information, visit EU-Startups.
